Outlook Therapeutics (OTLK) Other financing activities (2016 - 2025)
Outlook Therapeutics (OTLK) posted quarterly Other financing activities of $601914.0 for Q4 2025, down 89.62% quarter-over-quarter from $5.8 million in Q3 2025.
Outlook Therapeutics (OTLK) Other financing activities (2016 - 2025) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Other financing activities for 8 consecutive years, with $601914.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities changed N/A year-over-year to $601914.0; the TTM figure through Mar 2026 stood at $6.4 million (changed N/A YoY), while the FY2025 annual figure was $22.6 million, changed N/A from the prior year.
- Other financing activities retreated to $601914.0 in Q4 2025 per OTLK's latest filing, from $5.8 million in the prior quarter.
- Across five years, Other financing activities topped out at $5.8 million in Q3 2025 and bottomed at -$582250.0 in Q2 2022.
- Historically, Other financing activities has averaged $1.1 million across 4 years, with a median of $575590.0 in 2022.
- On a YoY basis, Other financing activities climbed as much as 7590.53% in 2022 and fell as far as 83.73% in 2022.
- Outlook Therapeutics' Other financing activities stood at $17750.0 in 2021, then jumped by 3105.24% to $568930.0 in 2022, then tumbled by 55.19% to $254964.0 in 2023, then surged by 136.08% to $601914.0 in 2025.
- Business Quant data shows OTLK's Other financing activities at $601914.0 in Q4 2025, $5.8 million in Q3 2025, and $254964.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 601,914.00 |
| Dec 31, 2025 | 601,914.00 |
| Sep 30, 2025 | 5.80 Mn |
| Sep 30, 2025 | 5.80 Mn |
| Mar 31, 2023 | 254,964.00 |
| Mar 31, 2023 | 254,964.00 |
| Dec 31, 2022 | 568,930.00 |
| Dec 31, 2022 | 568,930.00 |
| Sep 30, 2022 | 582,250.00 |
| Sep 30, 2022 | 582,250.00 |
| Jun 30, 2022 | -582,250.00 |
| Jun 30, 2022 | -582,250.00 |
| Mar 31, 2022 | 582,250.00 |
| Mar 31, 2022 | 582,250.00 |
| Dec 31, 2021 | 17,750.00 |
| Dec 31, 2021 | 17,750.00 |
| Sep 30, 2021 | 7,571.00 |
| Sep 30, 2021 | 7,571.00 |
| Mar 31, 2021 | 3.58 Mn |
| Mar 31, 2021 | 3.58 Mn |